As­traZeneca auc­tions off more as­sets in $766M deal, re­ports pos­i­tive da­ta for Farx­i­ga

⇨ As­traZeneca CEO Pas­cal So­ri­ot has sold off an­oth­er set of as­sets. The phar­ma gi­ant is sell­ing a port­fo­lio of anes­thet­ics to As­pen Glob­al for $555 mil­lion in cash and $211 mil­lion in mile­stones. As­traZeneca has been steadi­ly auc­tion­ing off a va­ri­ety of as­sets as it fo­cus­es more and more on its new can­cer fran­chise.

⇨ As­traZeneca has rolled out new da­ta from a late-stage study that high­lights how Farx­i­ga, ap­proved for Type 2 di­a­betes, al­so helps Type 1 pa­tients. That’s a much small­er mar­ket, but an open­ing here could ex­pand fran­chise sales. The drug is an SGLT-2 in­hibitor with sev­er­al ri­vals on the mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER